中文名:OSI-906(Linsitinib),雙重IGF-1R和胰島素受體激酶抑制劑
英文名:OSI-906 (Linsitinib)
中文別名:順式-3-[8-氨基-1-(2-苯基-7-喹啉基)咪唑并[1,5-A]吡嗪-3-基]-1-甲基環(huán)丁醇
英文別名:Linsitinib|867160-71-2|OSI-906|Linsitinib(OSI-906)|OSI906|OSI 906|OSI-906AA|OSI-906 (Linsitinib)|ASP-7487|3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol|15A52GPT8T|CHEMBL1091644|MMV676605|cis-3-(8-amino-1-(2-phenyl
純度:≥99%
貨號(hào):L126224
包裝:10mg、50mg、5mg
Cas號(hào):867160-71-2
存儲(chǔ)溫度:-20°C儲(chǔ)存
產(chǎn)品介紹:
Linsitinib is a potent, selective insulin-like growth factor-1 receptor (IGF-1R, IC50 = 35 nM) and insulin receptor (IR, IC50 = 75 nM) kinase inhibitor which works to block the autophosphorylation of IGF-1R and IR. Additionally, in vitro studies of Linsitinib have demonstrated its ability to inhibit the proliferation of multiple tumor cell lines.Linsitinib is a selective inhibitor of IGF-1R with IC50 of 35 nM, and modestly potent to InsR with IC50 of 75 nM, and has no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc.
查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對(duì)應(yīng)頁面:https://www.aladdin-e.com/zh_cn/L126224.html
關(guān)鍵字: 順式-3-[8-氨基-1-(2-苯基-7-喹啉基)咪唑并[1,5-A]吡嗪-3-基]-1-甲基環(huán)丁醇;Linsitinib;867160-71-2;OSI-906
上海阿拉丁生化科技股份有限公司是A股上市公司((股票代碼:688179),專注于科研試劑的研發(fā)、生產(chǎn)和銷售,已陸續(xù)建立多個(gè)工廠和研發(fā)中心。作為領(lǐng)軍企業(yè),阿拉丁始終堅(jiān)持質(zhì)量第一,連續(xù)13年被評(píng)為“最受歡迎試劑品牌”。
阿拉丁目前常備庫(kù)存試劑產(chǎn)品品種超過7萬種,SKU總數(shù)超過46萬,產(chǎn)品線涵蓋了化學(xué)試劑、生化試劑、藥靶配體、蛋白質(zhì)和抗體等多個(gè)領(lǐng)域,是國(guó)內(nèi)少數(shù)化學(xué)試劑到生物試劑全面發(fā)展的國(guó)產(chǎn)試劑品牌,產(chǎn)品同步發(fā)布在我們國(guó)內(nèi)(www.aladdin-e.com)和海外(www.aladdinsci.com)電商平臺(tái)。